Truvestments Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.17M Buy
9,959
+101
+1% +$22.4K 0.39% 65
2025
Q4
$2.25M Sell
9,858
-381
-4% -$86.8K 0.41% 71
2025
Q3
$2.37M Sell
10,239
-2,804
-21% -$571K 0.43% 70
2025
Q2
$2.42M Sell
13,043
-759
-5% -$141K 0.48% 62
2025
Q1
$2.89M Sell
13,802
-9,377
-40% -$1.82M 0.63% 57
2024
Q4
$4.12M Buy
23,179
+1,358
+6% +$250K 1.06% 13
2024
Q3
$4.31M Buy
21,821
+2,082
+11% +$389K 1.16% 11
2024
Q2
$3.39M Buy
19,739
+214
+1% +$35.4K 1.35% 11
2024
Q1
$3.56M Buy
19,525
+6,317
+48% +$1.09M 1.37% 11
2023
Q4
$2.05M Buy
13,208
+1,481
+13% +$216K 0.92% 36
2023
Q3
$1.75M Buy
11,727
+490
+4% +$71.9K 0.91% 41
2023
Q2
$1.51M Buy
11,237
+928
+9% +$136K 0.75% 54
2023
Q1
$1.64M Sell
10,309
-1,292
-11% -$198K 0.88% 50
2022
Q4
$1.87M Sell
11,601
-11,620
-50% -$1.78M 1.06% 31
2022
Q3
$3.12M Buy
23,221
+1,041
+5% +$149K 1.97% 8
2022
Q2
$3.4M Buy
22,180
+196
+0.9% +$29.9K 1.99% 7
2022
Q1
$3.56M Sell
21,984
-8
-0% -$1.16K 1.95% 9
2021
Q4
$2.98M Buy
21,992
+495
+2% +$58.5K 1.5% 12
2021
Q3
$2.32M Buy
21,497
+857
+4% +$97.9K 1.28% 20
2021
Q2
$2.33M Buy
20,640
+1,217
+6% +$137K 1.28% 20
2021
Q1
$2.1M Buy
19,423
+2,117
+12% +$226K 1.19% 15
2020
Q4
$1.85M Buy
17,306
+698
+4% +$67.1K 1.29% 11
2020
Q3
$1.45M Sell
16,608
-2,730
-14% -$257K 1.31% 14
2020
Q2
$1.9M Sell
19,338
-1,891
-9% -$166K 1.93% 8
2020
Q1
$1.62M Buy
21,229
+511
+2% +$43.5K 2.05% 7
2019
Q4
$1.83M Buy
20,718
+1,152
+6% +$95.6K 1.27% 23
2019
Q3
$1.48M Buy
19,566
+4,723
+32% +$324K 0.97% 28
2019
Q2
$1.08M Buy
14,843
+7,595
+105% +$597K 0.73% 38
2019
Q1
$584K Buy
+7,248
New +$593K 0.45% 63
2018
Q3
$1.37M Buy
14,512
+463
+3% +$43.9K 0.66% 38
2018
Q2
$1.3M Buy
+14,049
New +$1.37M 0.82% 33

Other funds holding ABBV

Truvestments Capital's ABBV Position: Q1 2026 in Review

Truvestments Capital increased its AbbVie (ABBV) stake by 1% in Q1 2026, buying an estimated $22.4K and bringing the position to 9,959 shares worth $2.17M. The position accounts for 0.39% of the portfolio, ranked #65.

Truvestments Capital first reported a position in ABBV in Q2 2018 and has held it in 31 quarters since. The position peaked at $4.31M in Q3 2024. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Truvestments Capital held 9,959 shares of AbbVie worth $2.17M as of Q1 2026.
  • Truvestments Capital bought 101 AbbVie shares in Q1 2026, an estimated $22.4K.
  • AbbVie made up 0.39% of Truvestments Capital's portfolio in Q1 2026, its #65 holding.
  • Truvestments Capital first reported a position in AbbVie in Q2 2018 and has held it in 31 quarters since.
  • Truvestments Capital's AbbVie position peaked at $4.31M in Q3 2024.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.